FMC Q1 2026 earnings call recap: guidance, debt paydown, India sale, Rynaxypyr post-patent strategy, and tariff/Iran risks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results